+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


China Cancer Early Detection Market Insight Report, 2021-2025

  • ID: 5359662
  • Report
  • May 2021
  • Region: China
  • 142 pages
  • AEI Research


  • Berry Oncology
  • Genetron Holdings Limited
The number of new cancer cases and deaths in China in 2020 was 456.9/3,003,000 respectively, ranking first in the world, and the five-year survival rate of cancer patients was only 40.5%(2015). Early screening can effectively reduce the incidence and mortality of cancer. Taking colorectal cancer as an example, the 5-year survival rate of early adenoma is close to 100%, while that of stage IV is only 10.8%. In the United States, the incidence of colorectal cancer is reduced by about 30% within 10 years after screening. The national Healthy China Action cancer prevention and control implementation plan clearly states that the overall 5-year survival rate of cancer in China should be no less than 43.3% and 46.6% by 2022 and 2030. The clinical value of early screening products is evaluated by sensitivity, specificity, PPV, NPV and other indicators, and the social benefits of early screening products are evaluated by health economics. High-performance early screening products can improve the dependence of patients, and have broad prospects under the encouragement of policies.

The demand for cancer early screening products is strong, and the applicable population base is huge. Taking colorectal cancer as an example, the China Anti-Cancer Association recommends that people aged 40-70 receive regular screening for colorectal cancer, among which 120 million are at high risk. According to our calculation, the corresponding market size of molecular diagnostic screening such as Fit-DNA is expected to reach 11.5 billion yuan in 2030, becoming the main early screening method. Screening for other cancers, including liver cancer, lung cancer, breast cancer, stomach cancer and cervical cancer, has the same clinical significance, and the penetration rate is expected to increase continuously, corresponding to the market scale of more than 10 billion yuan in 2030.

CtDNA enrichment, sequencing and genetic information interpretation technology continue to break through, and methylation and omics+big data methodology represent the future research and development direction; Large-scale, multicenter and prospective clinical trials are necessary and insufficient conditions for early screening products to be certified; In terms of commercialization, IVD product model is parallel to LDT service model, and the latter is expected to become a way for many innovative early screening products with its low cost under the background of deregulation.
Note: Product cover images may vary from those shown


  • Berry Oncology
  • Genetron Holdings Limited
1 Overview
1.1 Change the trajectory, and the early screening of tumors carries the market of 100 billion yuan
1.2 Innovation, early screening of tumors and cohesion of innovation vitality
1.3 Strategy is king, and early screening of tumor refers to medical health

2. Technical path of early screening of tumors
2.1 The economy of early screening of tumor anchored by markers and technology platform
2.2 New trend of early screening technology for tumor formation with multi-omics and low flux
2.3 Data wins, and colorectal cancer and liver cancer make the fastest progress in early screening

3 Compliance strategy for early screening of tumors
3.1 Retrospective and prospective clinical studies to locate the early screening function of tumor
3.2 Preempting the layout and promoting large-scale prospective trials are the mainstream strategies
3.3 High-input, high-risk, prospective clinical research 3 key points

4 Business model of early screening of tumors
4.1 From the laboratory to the terminal, the tumor missed the last mile early
4.2 Leveraging the B-side network, the penetration of the centralized mode is obviously insufficient
4.3 The final guess of early screening of tumors: directly serving the C-end population

5 Typical case of early screening of tumor

Selected Charts
Figure 1: Distribution of new cancer cases in the world by country in 2020
Figure 2: Distribution of global cancer deaths by country in 2020
Figure 3: New cancer cases/deaths in China in 2015/2020 (10,000 people)
Figure 4: Distribution of new cancer cases/deaths in China by cancer species in 2020
Figure 5: Early screening and diagnosis can greatly improve the survival rate of colorectal cancer patients
Figure 6: Incidence and mortality of colorectal cancer in the United States (1930-2017)
Figure 7: Screening/test result interpretation contingency table
Figure 8: PPV/NPV depends on the prevalence rate when the product performance is determined
Figure 9: Incidence of various cancers in China (2015, cases/100,000 people)
Figure 10: Under the same principle, the false positive and false negative rates cannot be reduced at the same time
Figure 11: roc curve and AUC area are comprehensive indicators of product performance
Figure 12: There is a strong correlation between the incidence of thyroid cancer in Korea and the screening penetration rate
Figure 13: Incidence and mortality of thyroid cancer after large-scale screening in Korea
Figure 14: Number of articles published in health economics evaluation of cancer screening in China
Figure 15: Screening Techniques Used in Health Economics Evaluation of Cancer Screening (2020)
Figure 16: The driving force of tumor screening in the market of 100 billion yuan
Figure 17: Population recommended for colorectal cancer screening in China
Figure 18: Screening penetration rate of colorectal cancer in China
Figure 19: Diagnosis process of primary liver cancer
Figure 20: progression of liver cancer and changes of tumor volume and plasma ctDNA level
Figure 21: Detection of Helicobacter pylori is an important part of gastric cancer screening
Figure 22: Population and screening penetration rate recommended for gastric cancer screening in China
Figure 23: Market size (IVD ex-factory price) and growth rate of gastric cancer screening in China
Figure 24: Population and screening penetration rate of cervical cancer screening in China
Figure 25: Market size and growth rate of cervical cancer screening in China
Figure 26: The cost of gene sequencing has dropped exponentially
Figure 27: The proportion of NGS large Panel in tumor treatment is increasing
Figure 28: Tumor metastasis and tumor components in blood
Figure 29: Early screening has the fastest growth rate in the application field of liquid biopsy subdivision
Figure 30: Number of new enterprises in China's liquid biopsy industry (home)
Figure 31: The proportion of enterprises in the liquid biopsy industry in China (2018)
Figure 32: The 20 most common gene mutations in various cancers
Figure 33: CT DNA is strongly correlated with the mutation frequency of driving genes in tissue biopsy cohort
Figure 34: Factors affecting the sensitivity of plasma cfDNA detection
Figure 35: Tumor size and the possibility of detection by ctDNA analysis
Figure 36: Mutation frequency caused by clonal hematopoiesis of each gene in cfDNA samples of common cancers
Figure 37: DNA methylation and carcinogenesis
Figure 38: CT DNA methylation method successfully identifies the location of colon cancer and lung cancer
Figure 39: Big data information based on multi-group science helps achieve accurate diagnosis and treatment
Figure 40: Clinical implementation stage of biomarker development for screening purposes
Figure 41: the cancer detection rate of CancerSEEK liquid biopsy in detect-a prospective study is only 26/96
Figure 42: Process from product development to commercialization under LDT and IVD modes
Note: Product cover images may vary from those shown
  • New Horizon Health Limited
  • Burning Rock Biotech Limited
  • Genetron Holdings Limited
  • Singlera Genomics Incorporated
  • Berry Oncology
Note: Product cover images may vary from those shown